![]() |
市場調查報告書
商品編碼
1662647
碘化鉀市場至2030年的預測:按類型、形式、等級、應用和地區的全球分析Potassium Iodide Market Forecasts to 2030 - Global Analysis By Type (Solid, Liquid, and Other Types), Form, Grade, Application and By Geography |
根據 Stratistics MRC 的資料,全球碘化鉀市場估計2024年將達到 10.6718億美元,到2030年將達到 18.396億美元,年複合成長率為 9.5%。
碘化鉀(KI)是由鉀和碘組成的化合物。碘化鉀常用於醫療、工業和食品領域。在醫學上,它主要用於預防碘缺乏症和在輻射緊急情況下保護甲狀腺。在食品工業中,將碘化鉀添加到食鹽中製成碘鹽,有助於預防碘缺乏症。此外,它們還可用於化學合成、攝影和作為實驗室試劑。
根據世界衛生組織(WHO)統計,全球約有18億人患有碘缺乏症。根據國際組織報告,全球有超過10%的人口無法獲得碘鹽。
碘缺乏情況加劇
缺乏碘仍然是影響全球數百萬人的主要公共衛生問題,特別是在缺乏富碘食物的地區。碘化鉀作為可靠的碘來源,用於生產碘鹽,對於預防碘缺乏症非常重要。為了解決碘缺乏問題,包括甲狀腺功能障礙和發育障礙,政府和衛生組織提倡使用碘鹽。隨著人們對碘缺乏健康危害的認知不斷提高,食品中對碘化鉀的需求也不斷增加。
副作用和過度使用問題
碘化鉀市場的一個主要障礙是對副作用和濫用的擔憂。儘管碘化鉀能有效治療碘缺乏症並保護甲狀腺免受輻射照射,但如果使用不當或過量,可能會導致許多健康問題。長期過量攝取的碘會損害甲狀腺功能並對健康產生不利影響。這些風險使得一些消費者和健康專家對使用碘化鉀猶豫不決,特別是將其用作膳食補充劑或緊急情況。因此,嚴格的規定和劑量指南對於減少這些擔憂非常重要。
不斷擴張的製藥業
碘化鉀用於治療多種甲狀腺疾病,包括碘缺乏症、甲狀腺腫和甲狀腺功能亢進。碘化鉀用於治療各種甲狀腺疾病,包括碘缺乏症、甲狀腺腫和甲狀腺功能亢進症,在輻射防護中也發揮重要作用,特別是在發生核電事故時。隨著全球製藥業因醫療需求的增加和治療的進步而不斷發展,藥物對碘化鉀的需求也不斷增加。特別是醫療保健基礎設施快速改善的新興市場,為該成長做出了貢獻。此外,對碘化鉀在癌症治療和藥物製劑等領域的新治療應用的持續研究進一步推動市場擴張。
原物料價格波動
碘化鉀生產的主要原料是碘,受供需失衡、地緣政治緊張局勢及產能變化等因素影響,碘價格可能大幅波動。碘主要從鹽水和海藻中提取,但某些地區的供應有限,且價格波動較大。原物料價格的波動直接影響碘化鉀的生產成本,有可能提高市場價格並影響碘鹽和藥品的可負擔性。因此,製造商可能面臨維持價格穩定和盈利的挑戰,這可能會阻礙市場成長。
COVID-19 的影響
COVID-19 疫情以多種方式影響了碘化鉀市場。一方面,全球供應鏈中斷,影響碘化鉀生產與流通,導致部分地區出現供不應求。另一方面,疫情提高了公眾的健康意識,包括對碘對維持甲狀腺健康的重要性的認知,並導致對食品和藥品用碘鹽和碘化鉀的需求增加。在疫情期間,對健康和保健的關注幫助市場復甦。
預計在預測期內,固態區隔將成為最大的。
由於固體材料廣泛應用於製藥、食品製造和化學工業等各個領域,預計在預測期內固態材料將佔據最大的市場佔有率。固體碘化鉀是製作碘鹽的首選,因為它易於處理和儲存。在醫學上,它通常以錠劑或口服液形式用於治療碘缺乏症和甲狀腺疾病。此外,固體形式的穩定性和成本效益也使其在化學合成和其他工業程中得到越來越廣泛的應用。
預計預測期內化學合成部門將以最高的年複合成長率成長。
由於化學合成領域在各種有機和無機化學反應中作為試劑的重要作用,預計在預測期內將呈現最高的成長率。碘化鉀在化學工業中廣泛用於生產碘基化合物、催化劑及中間體。碘化鉀促進鹵化和還原反應等過程,在藥品、農藥和其他特殊化學品的生產中非常重要。它的多功能性、有效性和提高反應效率的能力繼續推動化學合成應用的需求。
由於印度和中國等國家對碘缺乏問題的認知不斷提高以及碘鹽的採用,預計亞太地區將在預測期內佔據最大的市場佔有率。該地區的製藥和食品業日益擴大,進一步推動了醫療保健和食品強化對碘化鉀的需求。此外,日本等擁有核能計畫的國家對輻射安全的日益擔憂也促進了市場的成長。經濟發展、醫療保健服務的改善和政府措施也是推動該地區市場發展的關鍵因素。
預計北美地區在預測期內將呈現最高的年複合成長率。這是因為,食品中碘鹽的使用量不斷增加,推動了需求成長,尤其是在美國和加拿大。此外,製藥業的成長,特別是基於碘的治療,也促進了市場擴張。碘化鉀對於緊急情況下的輻射防護也非常重要,因此在有核能設施的地區也採用它。強大的醫療保健基礎設施和政府法規進一步推動北美市場的成長。
According to Stratistics MRC, the Global Potassium Iodide Market is accounted for $1067.18 million in 2024 and is expected to reach $1839.60 million by 2030 growing at a CAGR of 9.5% during the forecast period. Potassium iodide (KI) is a chemical compound made up of potassium and iodine. It is commonly used in medical, industrial, and food applications. In healthcare, it is primarily used to prevent iodine deficiency and protect the thyroid gland during radiation emergencies. In the food industry, potassium iodide is added to salt to create iodized salt, which helps prevent iodine deficiency. Additionally, it has applications in chemical synthesis, photography, and as a reagent in laboratory experiments.
According to the World Health Organization, an approximated 1.8 billion people worldwide have iodine deficiency. The report by the international agency also states that more than 10 of the world's population do not have access to iodized salt.
Rising incidence of iodine deficiency
Iodine deficiency continues to be a major public health concern that affects millions of people worldwide, especially in areas with restricted access to iodine-rich food sources. As a dependable source of iodine, potassium iodide which is mostly utilized in the manufacturing of iodized salt is essential in resolving this insufficiency. In order to address iodine deficient illnesses, including thyroid dysfunction and developmental problems, governments and health groups have been advocating for the usage of iodized salt. The need for potassium iodide in food products is rising as people become more conscious of the health hazards linked to iodine shortage.
Side effects and overuse concerns
Significant barriers to the potassium iodide market include side effects and worries about misuse. Despite its effectiveness in treating iodine deficiency and shielding the thyroid from radiation exposure, potassium iodide can cause a number of health issues if used incorrectly or in excess. Excessive iodine consumption over time can interfere with thyroid function and have negative health effects. Some consumers and medical experts are hesitant to use potassium iodide because of these hazards, especially in areas where it is utilized as a supplement or in emergency situations. Therefore, stringent regulation and dose guidelines are essential to reducing these worries.
Expanding pharmaceutical industry
Potassium iodide is used in the treatment of various thyroid disorders, including iodine deficiency, goiter, and hyperthyroidism. It also plays a crucial role in radiation protection, particularly in cases of nuclear accidents. As the global pharmaceutical industry grows, driven by increasing healthcare needs and advancements in medical treatments, the demand for potassium iodide in pharmaceuticals continues to rise. Emerging markets, where healthcare infrastructure is rapidly improving, are particularly contributing to this growth. Furthermore, ongoing research into new therapeutic applications of potassium iodide in areas such as cancer treatment and drug formulations further fuels the market's expansion.
Fluctuations in raw material prices
The primary raw material for potassium iodide production is iodine, and its price can be highly volatile due to factors such as supply-demand imbalances, geopolitical tensions, and changes in production capabilities. Iodine is primarily extracted from brine and seaweed, and its limited supply from specific regions makes it susceptible to price volatility. These fluctuations in raw material prices directly impact the cost of potassium iodide production, potentially increasing market prices and affecting the affordability of iodized salt and pharmaceutical products. As a result, manufacturers may face challenges in maintaining price stability and profitability, which can hinder market growth.
Covid-19 Impact
The COVID-19 pandemic had a mixed impact on the potassium iodide market. On one hand, the disruption in global supply chains affected the production and distribution of potassium iodide, leading to shortages in some regions. On the other hand, the pandemic heightened awareness about public health, including the importance of iodine in maintaining thyroid health, drives increased demand for iodized salt and potassium iodide in food and pharmaceutical applications. The focus on health and wellness during the pandemic contributed to the market's recovery.
The solid segment is expected to be the largest during the forecast period
The solid segment is expected to account for the largest market share during the forecast period, due to its widespread use in various applications, including pharmaceuticals, food production, and chemical industries. Solid potassium iodide is preferred in manufacturing iodized salt, as it is easier to handle and store. In pharmaceuticals, it is commonly used in the form of tablets or oral solutions for treating iodine deficiency and thyroid disorders. Additionally, the solid form's stability and cost-effectiveness contribute to its increasing adoption in chemical synthesis and other industrial processes.
The chemical synthesis segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the chemical synthesis segment is predicted to witness the highest growth rate, owing to its essential role as a reagent in various organic and inorganic chemical reactions. It is widely used in the production of iodine-based compounds, catalysts, and intermediates in the chemical industry. Potassium iodide facilitates processes like halogenation and reduction reactions, making it indispensable in the manufacture of pharmaceuticals, agrochemicals, and other specialty chemicals. Its versatility, effectiveness, and ability to enhance reaction efficiency continue to fuel its demand in chemical synthesis applications.
During the forecast period, Asia Pacific region is expected to hold the largest market share, driven by the increasing awareness of iodine deficiency and the adoption of iodized salt in countries like India and China. The region's expanding pharmaceutical and food industries further fuel demand for potassium iodide in healthcare and food fortification. Additionally, growing concerns about radiation safety in countries with nuclear energy programs, such as Japan, contribute to the market's growth. Economic development, improved healthcare access, and government initiatives are also key factors driving the market in the region.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to the increasing use of iodized salt in food products, especially in the U.S. and Canada, supports demand. Additionally, the pharmaceutical industry's growth, particularly for iodine-based treatments, contributes to market expansion. Potassium iodide is also crucial for radiation protection in emergency situations, boosting its adoption in regions with nuclear facilities. Strong healthcare infrastructure and government regulations further drive market growth in North America.
Key players in the market
Some of the key players profiled in the Potassium Iodide Market include Nippon Chemical Industrial Co., Ltd., Iochem Corporation, ABCR GmbH & Co. KG, Merck Group, Fisher Scientific, PVS Chemicals, Inc., Tianjin Zhonglian Pharmaceutical Co., Ltd., Sisco Research Laboratories Pvt. Ltd., Shandong Lianmeng Chemical Group Corporation, Hubei Xinjing Science and Technology Co., Ltd., Avidity Science, BASF SE, Jiangsu Jiamai Technology Co., Ltd., Zhejiang Xinxin Chemical Industry Co., Ltd., and Lianyungang Yizhou Pharmaceutical Co., Ltd.
In January 2025, Merck acquires HUB organoids holding b.v., expands next-gen biology portfolio. Merck announced the closing of the transaction to acquire HUB Organoids Holding B.V. (HUB) following regulatory clearances and the fulfilment of other customary closing conditions.
In June 2023, Tianjin Tianyao Pharmaceuticals Co.,Ltd. announced that it had received the Notice of Approval for the Launching Application of Chemical APIs for Travoprost approved and issued by National Medical Products Administration, and the preparation corresponding to Travoprost was mainly Travoprost eye drops.
In November 2021, Thermo Fisher Scientific introduced a new line of potassium iodide powder for laboratory and industrial applications, including chemical synthesis and other production processes.